Babu Yarlagadda S 4
4 · BIOCRYST PHARMACEUTICALS INC · Filed Nov 16, 2022
Insider Transaction Report
Form 4
Babu Yarlagadda S
VP Drug Discovery
Transactions
- Sale
Common Stock
2022-11-14$13.88/sh−31,515$437,428→ 298,541 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2022-11-14−50,000→ 0 totalExercise: $1.42From: 2014-01-01Exp: 2023-01-01→ Common Stock (50,000 underlying) - Exercise/Conversion
Common Stock
2022-11-14$1.42/sh+50,000$71,000→ 280,056 total - Exercise/Conversion
Common Stock
2022-11-14$1.42/sh+50,000$71,000→ 330,056 total - Exercise/Conversion
Emp. Stock Option (Right to Buy)
2022-11-14−50,000→ 0 totalExercise: $1.42From: 2014-01-01Exp: 2023-01-01→ Common Stock (50,000 underlying)
Footnotes (3)
- [F1]The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $13.86 to $13.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
- [F2]Annual Employee Option Grant became exercisable in four equal annual installments, beginning on this date.
- [F3]Retention Employee Stock Option became exercisable in two equal annual installments, beginning on this date.